The Tarrytown, New York-based company said it had net income of $8.06 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $12.07 per share. The results exceeded ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

Regeneron hosted a celebration to recognize the achievements of the 17 students selected as the Westchester 2025 Regeneron Science Talent Search Scholars. Beginning in 1942, the contest […] ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on Tuesday said its board ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Through the generous support of Regeneron, four times a year River Journal publishes the on-site report of a high school science student from the River Towns who is paired with a Regeneron […] ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...